Business Context and Reporting Period
Company: Emergent BioSolutions Inc.
Filing Type: Form 8-K (Current Report)
Report Date: January 10, 2012 (Event Date)
Subject: Entry into a Material Definitive Agreement regarding a contract modification with the Biomedical Advanced Research and Development Authority (BARDA).
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document reports a specific contractual event rather than periodic financial performance.
Material Changes
- Contract Modification: Emergent Product Development Gaithersburg Inc. (a wholly-owned subsidiary) entered into a no-cost modification of a contract dated September 17, 2010, with BARDA.
- Project Scope: Development of a recombinant protective antigen (rPA) anthrax vaccine.
- Timeline Extension: The base period of performance was extended from September 19, 2010, through September 18, 2012, to September 19, 2010, through January 20, 2013.
- Cost Impact: The modification is at no additional cost to the company.
- Deliverables: The Milestone Table and Deliverables were modified to align with the new performance period.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future outlook, or specific risk factors beyond the operational details of the contract extension. The primary implication is an extended timeline for the rPA anthrax vaccine development project without immediate additional funding.
Investor Verification Checklist
- Verify the impact of the extended timeline on the company's overall product development roadmap.
- Confirm whether the "no-cost" extension affects the total potential revenue or milestone payments associated with the original September 2010 contract.
- Review subsequent filings for any updates on the rPA anthrax vaccine development milestones.